(Q43950313)

28 November 2017

title

Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

28 November 2017

main subject

1 reference

1 reference

1 reference

Michael J Heard

1

1 reference

28 November 2017

Anita Pierce

series ordinal

2

1 reference

28 November 2017

Sandra A Carson

series ordinal

3

1 reference

28 November 2017

John E Buster

series ordinal

4

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

28 November 2017

published in

Fertility and Sterility

1 reference

28 November 2017

volume

77

1 reference

28 November 2017

issue

4

1 reference

28 November 2017

page(s)

669-673

1 reference

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903266-6

Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903266-6

Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903266-6

Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903266-6

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903266-6

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903266-6

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903266-6

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903266-6

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903266-6

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903266-6

Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903266-6

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903266-6

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903266-6

10.1016/S0015-0282(01)03266-6

7 January 2021

Identifiers

DOI

1 reference

28 November 2017

1 reference